The Fanconi anemia pathway and ICL repair: Implications for cancer therapy

Critical Reviews in Biochemistry and Molecular Biology

Volumn 45, Issue 5, 2010, Pages 424-439

  Wang, Lily C ^a   Gautier, Jean ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

checkpoint; crosslink; DNA repair; DNA replication; Fanconi anemia

Indexed keywords

ALKYLATING AGENT; ALSTERPAULLONE; BRCA1 PROTEIN; BRCA2 PROTEIN; CAMPTOTHECIN; CARBOPLATIN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CROSS LINKING REAGENT; CURCUMIN; DNA; FANCONI ANEMIA GROUP A PROTEIN; FANCONI ANEMIA GROUP C PROTEIN; FANCONI ANEMIA GROUP D2 PROTEIN; FANCONI ANEMIA GROUP E PROTEIN; FANCONI ANEMIA GROUP F PROTEIN; FANCONI ANEMIA GROUP G PROTEIN; FANCONI ANEMIA GROUP L PROTEIN; FANCONI ANEMIA PROTEIN; MELPHALAN; METHOXSALEN; MITOMYCIN C; N (2 AMINOETHYL) 5 ISOQUINOLINESULFONAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PSORALEN; PYRROLO[2,1 C][1,4]BENZODIAZEPINE DERIVATIVE; UNINDEXED DRUG; WORTMANNIN;

BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SUSCEPTIBILITY; CUTANEOUS T CELL LYMPHOMA; DIGESTIVE SYSTEM CANCER; DNA CROSS LINKING; DNA REPAIR; DNA REPLICATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; FANCONI ANEMIA; GENE; GENE DISRUPTION; HUMAN; LUNG CANCER; NEOPLASM; NONHUMAN; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PSORIASIS; REVIEW; SOLID TUMOR; TESTIS CANCER; UBIQUITINATION; VITILIGO;

ANIMALS; DNA REPAIR; DNA REPLICATION; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP PROTEINS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; SIGNAL TRANSDUCTION;

VERTEBRATA;

EID: 77956775152     PISSN: 10409238     EISSN: 15497798     Source Type: Journal    
DOI: 10.3109/10409238.2010.502166     Document Type: Review

References (153)

1. Ali AM, Singh TR and Meetei AR. 2009. FANCM-FAAP24 and FANCJ: FA proteins that metabolize DNA. Mutat Res 668:20-26.
2. Alpi A, Langevin F, Mosedale G, Machida YJ, Dutta A and Patel KJ. 2007. UBE2T, the Fanconi anemia core complex, and FANCD2 are recruited independently to chromatin: a basis for the regulation of FANCD2 monoubiquitination. Mol Cell Biol 27:8421-8430.
3. Alpi AF, Pace PE, Babu MM and Patel KJ. 2008. Mechanistic insight into site-restricted monoubiquitination of FANCD2 by Ube2t, FANCL, and FANCI. Mol Cell 32:767-777.
4. Andreassen PR, D'Andrea AD and Taniguchi T. 2004. ATR couples FANCD2 monoubiquitination to the DNA-damage response. Gene Dev 18:1958-1963.
5. Aris SM and Farrell NP. 2009. Towards Antitumor Active trans-Platinum Compounds. Eur J Inorg Chem 2009:1293.
6. Auerbach AD. 1993. Fanconi anemia diagnosis and the diepoxybutane (DEB) test. Exp Hematol 21:731-733.
7. Averbeck D, Papadopoulo D and Moustacchi E. 1988. Repair of 4,5′,8-trimethylpsoralen plus light-induced DNA damage in normal and Fanconi's anemia cell lines. Cancer Res 48:2015-2020.
8. Barroso E, Milne RL, Fernandez LP, Zamora P, Arias JI, Benitez J and Ribas G. 2006. FANCD2 associated with sporadic breast cancer risk. Carcinogenesis 27:1930-1937.
9. Beljanski V, Marzilli LG and Doetsch PW. 2004. DNA damage-processing pathways involved in the eukaryotic cellular response to anticancer DNA cross-linking drugs. Mol Pharmacol 65:1496-1506.
10. Ben-Yehoyada M, Wang LC, Kozekov ID, Rizzo CJ, Gottesman ME and Gautier J. 2009. Checkpoint signaling from a single DNA inter-strand crosslink. Mol Cell 35:704-715.
11. Bergstralh DT and Sekelsky J. 2008. Interstrand crosslink repair: can XPF-ERCC1 be let of the hook? Trends Genet 24:70-76.
12. Bhagwat N, Olsen AL, Wang AT, Hanada K, Stuckert P, Kanaar R, D'Andrea A, Niedernhofer LJ and McHugh PJ. 2009. XPF-ERCC1 participates in the Fanconi anemia pathway of cross-link repair. Mol Cell Biol 29:6427-6437.
13. Bodell WJ, Aida T and Rasmussen J. 1985. Comparison of sister-chro-matid exchange induction caused by nitrosoureas that alkylate or alkylate and crosslink DNA. Mutat Res 149:95-100.
14. Brabec V and Leng M. 1993. DNA interstrand cross-links of trans-diamminedichloroplatinum(II) are preferentially formed between guanine and complementary cytosine residues. Proc Natl Acad Sci USA 90:5345-5349.
15. Burkitt K and Ljungman M. 2008. Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin. Mol Cancer 7:24.
16. Cantor SB, Bell DW, Ganesan S, Kass EM, Drapkin R, Grossman S, Wahrer DC, Sgroi DC, Lane WS, Haber DA, et al. 2001. BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell 105:149-160.
17. Chen Q, Van der Sluis PC, Boulware D, Hazlehurst LA and Dalton WS. 2005. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood 106: 698-705.
18. Ciccia A, Ling C, Coulthard R, Yan Z, Xue Y, Meetei AR, Laghmani el H, Joenje H, McDonald N, de Winter JP, et al. 2007. Identifcation of FAAP24, a Fanconi anemia core complex protein that interacts with FANCM. Mol Cell 25:331-343.
19. Cipak L, Watanabe N and Bessho T. 2006. The role of BRCA2 in replication-coupled DNA interstrand cross-link repair in vitro. Nature Struct Mol Biol 13:729-733.
20. Clingen PH, De Silva IU, McHugh PJ, Ghadessy FJ, Tilby MJ, Turston DE and Hartley JA. 2005. The XPF-ERCC1 endonuclease and homologous recombination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1-c][1,4]benzodiazepine dimer SJG-136. Nucleic Acids Res 33:3283-3291.
21. Cohn MA, Kowal P, Yang K, Haas W, Huang TT, Gygi SP and D'Andrea AD. 2007. A UAF1-containing multisubunit protein complex regulates the Fanconi anemia pathway. Mol Cell 28:786-797.
22. Cole RS. 1973. Repair of DNA containing interstrand crosslinks in Escherichia coli: sequential excision and recombination. Proc Natl Acad Sci USA 70:1064-1068.
23. Collins NB, Wilson JB, Bush T, Tomashevski A, Roberts KJ, Jones NJ and Kupfer GM. 2009. ATR-dependent phosphorylation of FANCA on serine 1449 after DNA damage is important for FA pathway function. Blood 113:2181-2190.
24. Collis SJ, Ciccia A, Deans AJ, Horejsi Z, Martin JS, Maslen SL, Skehel JM, Elledge SJ, West SC and Boulton SJ. 2008. FANCM and FAAP24 function in ATR-mediated checkpoint signaling independently of the Fanconi anemia core complex. Mol Cell 32:313-324.
25. Couch FJ, Johnson MR, Rabe K, Boardman L, McWilliams R, de Andrade M and Petersen G. 2005. Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res 65:383-386.
26. de Winter JP and Joenje H. 2009. The genetic and molecular basis of Fanconi anemia. Mutat Res 668:11-19.
27. Dorsman JC, Levitus M, Rockx D, Rooimans MA, Oostra AB, Haitjema A, Bakker ST, Steltenpool J, Schuler D, Mohan S, et al. 2007. Identifcation of the Fanconi anemia complementation group I gene, FANCI. Cell Oncol 29:211-218.
28. Dronkert ML and Kanaar R. 2001. Repair of DNA interstrand crosslinks. Mutat Res 486:217-247.
29. Erkko H, Xia B, Nikkila J, Schleutker J, Syrjakoski K, Mannermaa A, Kallioniemi A, Pylkas K, Karppinen SM, Rapakko K, et al. 2007. A recurrent mutation in PALB2 in Finnish cancer families. Nature.
30. Friedenson B. 2005. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed 7:60.
31. Fujii T, Toyooka S, Ichimura K, Fujiwara Y, Hotta K, Soh J, Suehisa H, Kobayashi N, Aoe M, Yoshino T, et al. 2008. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer 59:377-384.
32. Fujiwara Y. 1982. Defective repair of mitomycin C crosslinks in Fanconi's anemia and loss in confuent normal human and xero-derma pigmentosum cells. Biochim Biophys Acta 699:217-225.
33. Garcia MJ, Fernandez V, Osorio A, Barroso A, Fernandez F, Urioste M and Benitez J. 2009. Mutational analysis of FANCL, FANCM and the recently identifed FANCI suggests that among the 13 known Fanconi Anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition. Carcinogenesis 30:1898-1902.
34. Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, Hejna J, Grompe M and D'Andrea AD. 2001. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 7:249-262.
35. Gilman A and Philips FS. 1946. The Biological Actions and Terapeutic Applications of the B-Chloroethyl Amines and Sulfdes. Science 103:409-436.
36. Godthelp BC, van Buul PP, Jaspers NG, Elghalbzouri-Maghrani E, van Duijn-Goedhart A, Arwert F, Joenje H and Zdzienicka MZ. 2006a. Cellular characterization of cells from the Fanconi anemia complementation group, FA-D1/BRCA2. Mutat Res 601:191-201.
37. Godthelp BC, Wiegant WW, Waisfsz Q, Medhurst AL, Arwert F, Joenje H and Zdzienicka MZ. 2006b. Inducibility of nuclear Rad51 foci after DNA damage distinguishes all Fanconi anemia complementation groups from D1/BRCA2. Mutat Res 594:39-48.
38. Gregson SJ, Howard PW, Hartley JA, Brooks NA, Adams LJ, Jenkins TC, Kelland LR and Turston DE. 2001. Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efcient cross-linking ability and potent cytotoxicity. J Med Chem 44:737-748.
39. Grillari J, Katinger H and Voglauer R. 2007. Contributions of DNA interstrand cross-links to aging of cells and organisms. Nucleic Acids Res 35:7566-7576.
40. Hazlehurst LA, Enkemann SA, Beam CA, Argilagos RF, Painter J, Shain KH, Saporta S, Boulware D, Moscinski L, Alsina M, et al. 2003. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res 63:7900-7906.
41. Henriques JA and Moustacchi E. 1981. Interactions between mutations for sensitivity to psoralen photoaddition (pso) and to radiation (rad) in Saccharomyces cerevisiae. J Bacteriol 148:248-256.
42. Hess CJ, Ameziane N, Schuurhuis GJ, Errami A, Denkers F, Kaspers GJ, Cloos J, Joenje H, Reinhardt D, Ossenkoppele GJ, et al. 2008. Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia. Cell Oncol 30: 299-306.
43. Hirano S, Yamamoto K, Ishiai M, Yamazoe M, Seki M, Matsushita N, Ohzeki M, Yamashita YM, Arakawa H, Buerstedde JM, et al. 2005. Functional relationships of FANCC to homologous recombination, translesion synthesis, and BLM. EMBO J 24:418-427.
44. Hlavin EM, Smeaton MB, Noronha AM, Wilds CJ and Miller PS. 2010. Cross-link structure afects replication-independent DNA inter-strand cross-link repair in mammalian cells. Biochemistry.
45. Ho GP, Margossian S, Taniguchi T and D'Andrea AD. 2006. Phosphorylation of FANCD2 on two novel sites is required for mitomycin C resistance. Mol Cell Biol 26:7005-7015.
46. Honig B, Morison WL and Karp D. 1994. Photochemotherapy beyond psoriasis. J Am Acad Dermatol 31:775-790.
47. Ishiai M, Kitao H, Smogorzewska A, Tomida J, Kinomura A, Uchida E, Saberi A, Kinoshita E, Kinoshita-Kikuta E, Koike T, et al. 2008. FANCI phosphorylation functions as a molecular switch to turn on the Fanconi anemia pathway. Nature Struct Mol Biol 15:1138-1146.
48. Jacquemont C and Taniguchi T. 2007. Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer Res 67:7395-7405.
49. Jones JC, Zhen WP, Reed E, Parker RJ, Sancar A and Bohr VA. 1991. Gene-specifc formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells. J Biol Chem 266:7101-7107.
50. Kartalou M and Essigmann JM. 2001. Recognition of cisplatin adducts by cellular proteins. Mutat Res 478:1-21.
51. Kee Y, Kim JM and D'Andrea AD. 2009. Regulated degradation of FANCM in the Fanconi anemia pathway during mitosis. Gene Dev 23:555-560.
52. Kennedy RD and D'Andrea AD. 2005. The Fanconi Anemia/BRCA pathway: new faces in the crowd. Gene Dev 19:2925-2940.
53. Kim JM, Kee Y, Gurtan A and D'Andrea AD. 2008. Cell cycle-dependent chromatin loading of the Fanconi anemia core complex by FANCM/FAAP24. Blood 111:5215-5222.
54. Kim JM, Parmar K, Huang M, Weinstock DM, Ruit CA, Kutok JL and D'Andrea AD. 2009. Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype. Dev Cell 16:314-320.
55. Kleiner HE, Reed MJ and DiGiovanni J. 2003. Naturally occurring coumarins inhibit human cytochromes P450 and block benzo[a] pyrene and 7,12-dimethylbenz[a]anthracene DNA adduct formation in MCF-7 cells. Chem Res Toxicol 16:415-422.
56. Knipscheer P, Raschle M, Smogorzewska A, Enoiu M, Ho T V, Scharer OD, Elledge SJ and Walter JC. 2009. The Fanconi anemia pathway promotes replication-dependent DNA interstrand crosslink repair. Science 326:1698-1701.
57. Koberle B, Masters JR, Hartley JA and Wood RD. 1999. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 9:273-276.
58. Kozekov ID, Nechev LV, Moseley MS, Harris CM, Rizzo CJ, Stone MP and Harris TM. 2003. DNA interchain cross-links formed by acro-lein and crotonaldehyde. J Am Chem Soc 125:50-61.
59. Kumaresan KR and Lambert MW. 2000. Fanconi anemia, complementation group A, cells are defective in ability to produce incisions at sites of psoralen interstrand cross-links. Carcinogenesis 21:741-751.
60. Kumaresan KR, Sridharan DM, McMahon LW and Lambert MW. 2007. Defciency in incisions produced by XPF at the site of a DNA interstrand cross-link in Fanconi anemia cells. Biochemistry 46:14359-14368.
61. Kutler DI, Singh B, Satagopan J, Batish SD, Berwick M, Giampietro PF, Hanenberg H and Auerbach AD. 2003. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 101:1249-1256.
62. Lehoczky P, McHugh PJ and Chovanec M. 2007. DNA interstrand cross-link repair in Saccharomyces cerevisiae. FEMS Microbiol Rev 31:109-133.
63. Levitus M, Joenje H and de Winter JP. 2006. The Fanconi anemia pathway of genomic maintenance. Cell Oncol 28:3-29. (Pubitemid 43673124)
64. Lindahl T and Barnes DE. 2000. Repair of endogenous DNA damage. Cold Spring Harb Symp Quant Biol 65:127-133.
65. Ling C, Ishiai M, Ali AM, Medhurst AL, Neveling K, Kalb R, Yan Z, Xue Y, Oostra AB, Auerbach AD, et al. 2007. FAAP100 is essential for activation of the Fanconi anemia-associated DNA damage response pathway. The EMBO journal 26: 2104-2114.
66. Lohman, P.H. 1999. Qualitative and quantitative procedures for health risk assessment. Mutat Res 428: 237-254.
67. Longerich, S., San Filippo, J., Liu, D and Sung, P. 2009. FANCI binds branched DNA and is monoubiquitinated by UBE2T-FANCL. J Biol Chem 284, 23182-23186.
68. Luke-Glaser, S., Luke, B., Grossi, S and Constantinou, A. 2010. FANCM regulates DNA chain elongation and is stabilized by S-phase checkpoint signalling. The EMBO journal 29, 795-805.
69. Machida, Y.J., Machida, Y., Chen, Y., Gurtan, A.M., Kupfer, G.M., D'Andrea, A.D and Dutta, A. 2006. UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. Mol Cell 23, 589-596.
70. Mathew, C.G. 2006. Fanconi anaemia genes and susceptibility to cancer. Oncogene 25, 5875-5884.
71. McHugh PJ, Sones WR and Hartley JA. 2000. Repair of intermediate structures produced at DNA interstrand cross-links in Saccharomyces cerevisiae. Mol Cell Biol 20:3425-3433.
72. McHugh PJ, Spanswick VJ and Hartley JA. 2001. Repair of DNA inter-strand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol 2:483-490.
73. McVey M. 2010. Strategies for DNA interstrand crosslink repair: Insights from worms, fies, frogs, and slime molds. Environ Mol Mutagen.
74. Meetei AR, de Winter JP, Medhurst AL, Wallisch M, Waisfsz Q, van de Vrugt HJ, Oostra AB, Yan Z, Ling C, Bishop CE, et al. 2003. A novel ubiquitin ligase is defcient in Fanconi anemia. Nat Genet 35:165-170.
75. Meetei AR, Medhurst AL, Ling C, Xue Y, Singh TR, Bier P, Steltenpool J, Stone S, Dokal I, Mathew CG, et al. 2005. A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M. Nat Genet 37:958-963.
76. Mi J and Kupfer GM. 2005. The Fanconi anemia core complex associates with chromatin during S phase. Blood 105:759-766.
77. Mi J, Qiao F, Wilson JB, High AA, Schroeder MJ, Stukenberg PT, Moss A, Shabanowitz J, Hunt DF, Jones NJ, et al. 2004. FANCG is phosphorylated at serines 383 and 387 during mitosis. Mol Cell Biol 24:8576-8585.
78. Mirchandani KD, McCafrey RM and D'Andrea AD. 2008. The Fanconi anemia core complex is required for efcient point mutagenesis and Rev1 foci assembly. DNA Repair (Amst) 7:902-911.
79. Moldovan GL and D'Andrea AD. 2009. How the fanconi anemia pathway guards the genome. Annu Rev Genet 43:223-249.
80. Moynahan ME, Pierce AJ and Jasin M. 2001. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 7:263-272.
81. Muniandy PA, Tapa D, Tazhathveetil AK, Liu ST and Seidman MM. 2009. Repair of laser-localized DNA interstrand cross-links in G1 phase mammalian cells. J Biol Chem 284:27908-27917.
82. Muniandy PA, Liu J, Majumdar A, Liu ST and Seidman MM. 2010. DNA interstrand crosslink repair in mammalian cells: step by step. Crit Rev Biochem Mol Biol 45:23-49.
83. Naim V and Rosselli F. 2009. The FANC pathway and BLM collaborate during mitosis to prevent micro-nucleation and chromosome abnormalities. Nat Cell Biol 11:761-768.
84. Nakanishi K, Yang YG, Pierce AJ, Taniguchi T, Digweed M, D'Andrea AD, Wang ZQ and Jasin M. 2005. Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. Proc Natl Acad Sci USA 102:1110-1115.
85. Neumann B, Walter T, Heriche JK, Bulkescher J, Erfe H, Conrad C, Rogers P, Poser I, Held M, Liebel U, et al. 2010. Phenotypic profl-ing of the human genome by time-lapse microscopy reveals cell division genes. Nature 464:721-727.
86. Neveling K, Kalb R, Florl AR, Herterich S, Friedl R, Hoehn H, Hader C, Hartmann FH, Nanda I, Steinlein C, et al. 2007. Disruption of the FA/BRCA pathway in bladder cancer. Cytogenetic and genome research 118:166-176.
87. Niedernhofer LJ, Daniels JS, Rouzer CA, Greene RE and Marnett LJ. 2003. Malondialdehyde, a product of lipid peroxidation, is muta-genic in human cells. J Biol Chem 278:31426-31433.
88. Niedernhofer LJ, Lalai AS and Hoeijmakers JH. 2005. Fanconi anemia (cross)linked to DNA repair. Cell 123:1191-1198.
89. Niedzwiedz W, Mosedale G, Johnson M, Ong CY, Pace P and Patel KJ. 2004. The Fanconi anaemia gene FANCC promotes homologous recombination and error-prone DNA repair. Mol Cell 15:607-620.
90. Nijman SM, Huang TT, Dirac AM, Brummelkamp TR, Kerkhoven RM, D'Andrea AD and Bernards R. 2005. The deubiq-uitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell 17:331-339.
91. Noll DM, Mason TM and Miller PS. 2006. Formation and repair of interstrand cross-links in DNA. Chem Rev 106:277-301.
92. Oestergaard VH, Langevin F, Kuiken HJ, Pace P, Niedzwiedz W, Simpson LJ, Ohzeki M, Takata M, Sale JE and Patel KJ. 2007. Deubiquitination of FANCD2 is required for DNA crosslink repair. Mol Cell 28:798-809. (Pubitemid 350217050)
93. Pagano G. 2002. Redox-modulated xenobiotic action and ROS formation: a mirror or a window? Hum Exp Toxicol 21:77-81.
94. Patel KJ and Joenje H. 2007. Fanconi anemia and DNA replication repair. DNA Repair 6:885-890.
95. Pichierri P and Rosselli F. 2004a. Fanconi anemia proteins and the s phase checkpoint. Cell Cycle 3:698-700.
96. Pichierri P and Rosselli F. 2004b. The DNA crosslink-induced S-phase checkpoint depends on ATR-CHK1 and ATR-NBS1-FANCD2 pathways. EMBO J 23:1178-1187.
97. Pichierri P, Franchitto A and Rosselli F. 2004. BLM and the FANC proteins collaborate in a common pathway in response to stalled replication forks. EMBO J 23:3154-3163.
98. Potapova A, Hofman AM, Godwin AK, Al-Saleem T and Cairns P. 2008. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer. Cancer Res 68:998-1002.
99. Rajski SR and Williams RM. 1998. DNA cross-linking agents as antitu-mor drugs. Chem Rev 98:2723-2796.
100. Raschle M, Knipsheer P, Enoiu M, Angelov T, Sun J, Grifth JD, Ellenberger TE, Scharer OD and Walter JC. 2008. Mechanism of replication-coupled DNA interstrand crosslink repair. Cell 134:969-980.
101. Rink SM and Hopkins PB. 1995. A mechlorethamine-induced DNA interstrand cross-link bends duplex DNA. Biochemistry 34:1439-1445.
102. Roberts JJ and Friedlos F. 1987. Quantitative estimation of cispla-tin-induced DNA interstrand cross-links and their repair in mammalian cells: relationship to toxicity. Pharmacol Ter 34: 215-246.
103. Rogers CD, van der Heijden MS, Brune K, Yeo CJ, Hruban RH, Kern SE and Goggins M. 2004. The genetics of FANCC and FANCG in familial pancreatic cancer. Cancer Biol Ter 3:167-169. (Pubitemid 41350898)
104. Roques C, Coulombe Y, Delannoy M, Vignard J, Grossi S, Brodeur I, Rodrigue A, Gautier J, Stasiak AZ, Stasiak A, et al. 2009. MRE11-RAD50-NBS1 is a critical regulator of FANCD2 stability and function during DNA double-strand break repair. EMBO J 28:2400-2413.
105. Rosenberg B, Vancamp L and Krigas T. 1965. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205:698-699.
106. Sarkar S, Davies AA, Ulrich HD and McHugh PJ. 2006. DNA interstrand crosslink repair during G1 involves nucleotide excision repair and DNA polymerase zeta. EMBO J 25:1285-1294.
107. Schwab RA, Blackford AN and Niedzwiedz W. 2010. ATR activation and replication fork restart are defective in FANCM-defcient cells. EMBO J 29:806-818.
108. Shen X and Li L. 2010. Mutagenic repair of DNA interstrand crosslinks. Environ Mol Mutagen.
109. Shen X, Do H, Li Y, Chung WH, Tomasz M, de Winter JP, Xia B, Elledge SJ, Wang W and Li L. 2009. Recruitment of fanconi anemia and breast cancer proteins to DNA damage sites is diferen-tially governed by replication. Mol Cell 35:716-723.
110. Sims AE, Spiteri E, Sims 3rd RJ, Arita AG, Lach FP, Landers T, Wurm M, Freund M, Neveling K, Hanenberg H, et al. 2007. FANCI is a second monoubiquitinated member of the Fanconi anemia pathway. Nature Struct Mol Biol 14:564-567.
111. Sladek FM, Munn MM, Rupp WD and Howard-Flanders P. 1989. In vitro repair of psoralen-DNA cross-links by RecA, UvrABC, and the 5′-exonuclease of DNA polymerase I. J Biol Chem 264:6755-6765.
112. Smeaton MB, Hlavin EM, McGregor Mason T, Noronha AM, Wilds CJ and Miller PS. 2008. Distortion-dependent unhooking of inter-strand cross-links in mammalian cell extracts. Biochemistry 47:9920-9930.
113. Smeaton MB, Hlavin EM, Noronha AM, Murphy SP, Wilds CJ and Miller PS. 2009. Efect of cross-link structure on DNA inter-strand cross-link repair synthesis. Chem Res Toxicol 22: 1285-1297.
114. Smogorzewska A, Matsuoka S, Vinciguerra P, McDonald 3rd ER, Hurov KE, Luo J, Ballif BA, Gygi SP, Hofmann K, D'Andrea AD, et al. 2007. Identifcation of the FANCI protein, a monou-biquitinated FANCD2 paralog required for DNA repair. Cell 129:289-301.
115. Sobeck A, Stone S, Costanzo V, de Graaf B, Reuter T, de Winter J, Wallisch M, Akkari Y, Olson S, Wang W, et al. 2006. Fanconi anemia proteins are required to prevent accumulation of replication-associated DNA double-strand breaks. Mol Cell Biol 26:425-437.
116. Sobeck A, Stone S, Landais I, de Graaf B and Hoatlin ME. 2009. The Fanconi anemia protein FANCM is controlled by FANCD2 and the ATR/ATM pathways. J Biol Chem 284:25560-25568.
117. Sridharan D, Brown M, Lambert WC, McMahon LW and Lambert MW. 2003. Nonerythroid alphaII spectrin is required for recruitment of FANCA and XPF to nuclear foci induced by DNA interstrand cross-links. J Cell Sci 116:823-835.
118. Stark JM, Pierce AJ, Oh J, Pastink A and Jasin M. 2004. Genetic steps of mammalian homologous repair with distinct mutagenic consequences. Mol Cell Biol 24:9305-9316.
119. Stone MP, Cho YJ, Huang H, Kim HY, Kozekov ID, Kozekova A, Wang H, Minko IG, Lloyd RS, Harris TM, et al. 2008. Interstrand DNA cross-links induced by alpha,beta-unsaturated aldehydes derived from lipid peroxidation and environmental sources. Acc Chem Res 41:793-804.
120. Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N and Taniguchi T. 2008. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 68: 2581-2586.
121. Taniguchi T and D'Andrea AD. 2006. Molecular pathogenesis of Fanconi anemia: recent progress. Blood 107:4223-4233.
122. Taniguchi T, Garcia-Higuera I, Andreassen PR, Gregory RC, Grompe M and D'Andrea AD. 2002a. S-phase-specifc interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood 100:2414-2420.
123. Taniguchi T, Garcia-Higuera I, Xu B, Andreassen PR, Gregory RC, Kim ST, Lane WS, Kastan MB and D'Andrea AD. 2002b. Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways. Cell 109:459-472.
124. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, Mok SC and D'Andrea AD. 2003. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 9:568-574.
125. Tompson LH and Hinz JM. 2009. Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights. Mutat Res 668:54-72.
126. Tischkowitz M, Ameziane N, Waisfsz Q, De Winter JP, Harris R, Taniguchi T, D'Andrea A, Hodgson SV, Mathew CG and Joenje H. 2003. Bi-allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia. Br J Haematol 123:469-471.
127. Tomasz M. 1995. Mitomycin C: small, fast and deadly (but very selective). Chem Biol 2:575-579.
128. van der Heijden MS, Yeo CJ, Hruban RH and Kern SE. 2003. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 63:2585-2588.
129. Van Houten B, Gamper H, Hearst JE and Sancar A. 1988. Analysis of sequential steps of nucleotide excision repair in Escherichia coli using synthetic substrates containing single psoralen adducts. J Biol Chem 263:16553-16560.
130. Vaz F, Hanenberg H, Schuster B, Barker K, Wiek C, Erven V, Neveling K, Endt D, Kesterton I, Autore F, et al. 2010. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet 42: 406-409.
131. Vilmar A and Sorensen JB. 2008. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: A review of current literature. Lung cancer. Amsterdam: Netherlands.
132. Vogel EW, Nivard MJ, Ballering LA, Bartsch H, Barbin A, Nair J, Comendador MA, Sierra LM, Aguirrezabalaga I, Tosal L, et al. 1996. DNA damage and repair in mutagenesis and carcinogen-esis: implications of structure-activity relationships for cross-species extrapolation. Mutat Res 353:177-218.
133. Vogel EW, Barbin A, Nivard MJ, Stack HF, Waters MD and Lohman PH. 1998. Heritable and cancer risks of exposures to anticancer drugs: inter-species comparisons of covalent deox-yribonucleic acid-binding agents. Mutat Res 400:509-540.
134. Wang LC, Stone S, Hoatlin ME and Gautier J. 2008. Fanconi anemia proteins stabilize replication forks. DNA Repair (Amst).
135. Wang W. 2007. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 8:735-748.
136. Wang X, Peterson CA, Zheng H, Nairn RS, Legerski RJ and Li L. 2001. Involvement of nucleotide excision repair in a recombination-independent and error-prone pathway of DNA interstrand crosslink repair. Mol Cell Biol 21:713-720.
137. Wang X, Andreassen PR and D'Andrea AD. 2004. Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin. Mol Cell Biol 24:5850-5862.
138. Wang X, Kennedy RD, Ray K, Stuckert P, Ellenberger T and D'Andrea AD. 2007. Chk1-mediated phosphorylation of FANCE is required for the Fanconi anemia/BRCA pathway. Mol Cell Biol 27:3098-3108.
139. Warren AJ, Maccubbin AE and Hamilton JW. 1998. Detection of mito-mycin C-DNA adducts in vivo by 32P-postlabeling: time course for formation and removal of adducts and biochemical modulation. Cancer Res 58:453-461.
140. Welsh C, Day R, McGurk C, Masters JR, Wood RD and Koberle B. 2004. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer 110:352-361.
141. White MF. 2009. Structure, function and evolution of the XPD family of iron-sulfur-containing 5′→3′ DNA helicases. Biochem Soc Trans 37:547-551.
142. Wiencke JK and Wiemels J. 1995. Genotoxicity of 1,3-bis(2-chloroethyl)-1- nitrosourea (BCNU). Mutat Res 339:91-119.
143. Xia B, Dorsman J, De Vries Y, Ameziane N, Rooimans MA, Oostra AB, Sheng Q, Steltenpool J, Gluckman E, Llera J, et al. 2006a. PALB2, a New Member of the FA/BRCA Pathway. Paper presented at: Eighteenth Annual Fanconi Anemia Research Fund Scientifc Symposium.
144. Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, Liu X, Jasin M, Couch FJ and Livingston DM. 2006b. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 22:719-729.
145. Yaghi BM, Turner PM, Denny WA, Turner PR, O'Connor CJ and Ferguson LR. 1998. Comparative mutational spectra of the nitrogen mustard chlorambucil and its half-mustard analogue in Chinese hamster AS52 cells. Mutat Res 401:153-164.
146. Yamamoto K, Ishiai M, Matsushita N, Arakawa H, Lamerdin JE, Buerstedde JM, Tanimoto M, Harada M, Tompson LH and Takata M. 2003. Fanconi anemia FANCG protein in mitigating radiation-and enzyme-induced DNA double-strand breaks by homologous recombination in vertebrate cells. Mol Cell Biol 23:5421-5430.
147. Yamamoto K, Hirano S, Ishiai M, Morishima K, Kitao H, Namikoshi K, Kimura M, Matsushita N, Arakawa H, Buerstedde JM, et al. 2005. Fanconi anemia protein FANCD2 promotes immunoglobulin gene conversion and DNA repair through a mechanism related to homologous recombination. Mol Cell Biol 25:34-43.
148. Yang YG, Herceg Z, Nakanishi K, Demuth I, Piccoli C, Michelon J, Hildebrand G, Jasin M, Digweed M and Wang ZQ. 2005. The Fanconi anemia group A protein modulates homologous repair of DNA double-strand breaks in mammalian cells. Carcinogenesis 26:1731-1740.
149. Zhang J, Wang X, Lin CJ, Couch FJ and Fei P. 2006. Altered expression of FANCL confers mitomycin C sensitivity in Calu-6 lung cancer cells. Cancer Biol Ter 5:1632-1636.
150. Zheng H, Wang X, Warren AJ, Legerski RJ, Nairn RS, Hamilton JW and Li L. 2003. Nucleotide excision repair-and polymerase eta-mediated error-prone removal of mitomycin C interstrand cross-links. Mol Cell Biol 23:754-761.
151. Zhi G, Wilson JB, Chen X, Krause DS, Xiao Y, Jones NJ and Kupfer GM. 2009. Fanconi anemia complementation group FANCD2 protein serine 331 phosphorylation is important for fanconi anemia pathway function and BRCA2 interaction. Cancer Res 69:8775-8783.
152. Zhu W and Dutta A. 2006a. Activation of fanconi anemia pathway in cells with re-replicated DNA. Cell Cycle 5:2306-2309.
153. Zhu W and Dutta A. 2006b. An ATR-and BRCA1-mediated Fanconi anemia pathway is required for activating the G2/M checkpoint and DNA damage repair upon rereplication. Mol Cell Biol 26:4601-4611.